Warhound emerges from stealth with a $200M seed round to breed gene-edited military working dogs

TLDR

• Warhound left stealth with a $200M seed round to rebuild a domestic supply of military working dogs.¹
• TechCrunch reports a $1.2B valuation; the company release gives none. No lead investor is named in the sources.¹²
• Fortune reports no signed customers and no price per dog; the first dogs are about two years away.³

Warhound, a defence technology company conceived by Colossal Biosciences' Ben Lamm and Anduril's Palmer Luckey, emerged from stealth on 22 October 2026 with a $200 million seed round, according to its release.¹ The company says it will produce genetically enhanced working dogs for US military forces, law enforcement and emergency response teams, and cut reliance on a shrinking European supply.¹ TechCrunch reports that the round values the company at $1.2 billion; the release carries no valuation, so that figure rests on TechCrunch's reporting.¹² David Spirk, a former Marine, Pentagon chief data officer and Palantir senior counsellor, is chief executive and the company is based in Texas.¹⁴

The pitch is a supply-chain argument. The release says more than 80% of US military working dogs are bought from Europe, that the programme runs more than 2,200 dog teams, and that after a roughly three-year acquisition and training pipeline fewer than half of the dogs bought are fit for service, so about 200 must be sourced to field 100.¹ These figures are the company's own; TechCrunch and Fortune repeat them as the company's claims.²³ Warhound plans to biobank cell lines from top-performing dogs, clone proven animals and edit genes, using Colossal's genetics platform, with Colossal's Viagen unit helping to clone.¹² Anduril will supply protective and sensing equipment (the release calls it cybernetic "Augments"), which Lamm described to TechCrunch as "on top of the dog, not in the dog".¹²

On investors: the release names In-Q-Tel, Sequoia Capital, ARK Invest, Franklin Templeton, 8VC, USIT, Bob Nelsen, Breyer Capital, CAZ Investments, Neogenesis, Builders VC and Lux Capital "among others".¹ Fortune lists the same names, and TechCrunch singles out In-Q-Tel, Sequoia and 8VC.²³ None of the sources names a lead investor, and none says which backers are new or existing. On ownership, TechCrunch and WIRED report that Colossal holds equity, while Luckey holds none; WIRED adds that Anduril holds none either.²⁴ Lamm is on the board.³⁴

The second sources add different angles. Fortune adds the commercial picture: no signed customers, no per-dog price, and a "Canine-as-a-Service" model under discussion in which the government would buy a steady supply of trained dogs.³ It also notes that cloning working dogs is not new and says Lamm expects to deliver the first dogs in about two years.³ WIRED reports that the first batch is being gene-edited and puppies are expected in early 2027, starting with health conditions such as hip dysplasia, with possible later enhancements.⁴ TechCrunch says the first batch is expected to be born early next year and enter service within two years.² On origins, the release says the idea arose at Peter Diamandis' Moonshots Summit and TechCrunch says Lamm met Luckey about a year ago; the sources differ on timing.¹² No independent check of the supply figures, the cloning plans or government demand was found.

On the investors: In-Q-Tel's portfolio page lists Anduril and Watchtower Labs among its investments.⁵ Lux Capital's companies page lists Anduril, with a Lux investment dated 2017, and Applied Intuition, which it says builds autonomy for defence among other industries.⁶ The Sequoia and 8VC portfolio pages reviewed showed no defence companies in the portion read, and the sources name no defence holdings for the remaining backers.

Why it matters: a $200M seed for gene-edited working dogs shows investors backing a defence supply-chain pitch before any customer is signed, though the valuation is reported rather than confirmed and the supply and cloning claims are the company's own.¹²³